Select Page
thumbnail_Mockup Ebook AplusA DLBCL 2020 EN

Healthcare market research is working in an increasingly global and competitive context.

As a leading healthcare market research agency, AplusA has extensive experience researching diseases within hemato-oncology.

This eBook shares insights from our US and top-5 European Union (EU5) syndicated diffuse large B-cell lymphoma (DLBCL) market tracker.

The eBook provides a comprehensive market overview for marketers or market researchers working in this area. It includes:

DLBCL market overview

    • What regimens do hem/ons use to treat DLBCL?

    • Are any brands used off-label to treat the disease?

    • What companies market each brand?

    • Are generic or biosimilars available?

    • Where is usage increasing?

    • How aware are hem/oncs of various brands?

Treatment performance

    • What attributes govern choice?
    • What are the current barand and regimen shares in each line of therapy?

    • Are SCT or radiation important?

    • Are there treatment differences in SCT-eligible vs ineligible patients?

    • Is DLBCL maintenance therapy common?

    • How are regimens sequenced?

    • Are there common treatment durations?

Patient insights

    • Are there DLBCL variants
    • What is profile of DLBCL patients by line of therapy?
    • When were patients diagnosed?
    • How many were refactory?
    • How does the profile of SCT eligible vs ineligible patients differ?


PLUS patient journey insights from our additional social media intelligence research

Download the eBook now via the form on this page.

Download the dlbcl eBook